CTIS2023-510381-28-01进行中（未招募）1 期
A parallel-group treatment, Phase 4, prospective multicenter double-blind randomized 2-arm placebo-controlled study to investigate the effect of single dose topical administration of tranexamic acid vs placebo onto surgical wound surfaces on postoperative re-bleeding, wound complications, seroma and thromboembolic events in male and female patients above 18 years of age undergoing plastic surgery. - 270777
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Patients are to undergo a surgical procedure within the field of plastic surgery where the procedure involves use of topical TXA at the participating center., Patients are over 18 years of age and capable of independently providing informed consent., Patients have received adequate oral and written information about the study and signed the informed-consent form .
排除标准
- •Patients with known allergy to tranexamic acid.
研究者
相似试验
已完成
4 期
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR MutationCystic FibrosisNCT02875366Vertex Pharmaceuticals Incorporated70
进行中（未招募）
1 期
Commercial study conducted to determine the most adequate supplementation of vitamin D in patients showing vitamin D deficiencyPatients of 18 years of age or more with vitamin D deficiencyMedDRA version: 14.1Level: PTClassification code 10047626Term: Vitamin D deficiencySystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-004917-14-BEABORATOIRES SMB S.A
进行中（未招募）
4 期
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)Eosinophilic OesophagitisNCT06101095Sanofi69
进行中（未招募）
1 期
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered Daily in Subjects with Atopic DermatitisAtopic DermatitisEUCTR2021-006884-67-PLArcutis Biotherapeutics, Inc.650
进行中（未招募）
1 期
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic DermatitisAtopic DermatitisEUCTR2021-006903-14-PLArcutis Biotherapeutics, Inc.650